R01(Neoaniigen)

Primary Objective: To evaluate the safety and tolerability of R01 injection as adjuvant therapy in patients with malignant solid tumors at high risk of recurrence after radical surgery, providing a basis for dose selection in a phase II clinical trial. Secondary Objective: To evaluate the immunogenicity and preliminary efficacy of R01 injection as adjuvant therapy in patients with malignant solid tumors at high risk of recurrence after radical surgery. Exploratory Objective: To explore the pharmacokinetic characteristics of R01 injection in patients with malignant solid tumors at high risk of recurrence after radical surgery.